文献速递消化道肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗联合皮内注射热灭活分枝杆菌(IMM-101)疫苗治疗(改良)FOLFIRINOX诱导化疗后无进展局部晚期胰腺癌的可行性、安全性和疗效——LAPC-2试验

Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX - The LAPC-2 trial.
PubMed 文献 · Radiother Oncol · 2023-02-20

这项I/II期试验纳入38例(改良)FOLFIRINOX化疗后无进展的局部晚期胰腺癌患者,接受SBRT(总剂量40 Gy,每次8 Gy,连续5天)联合IMM-101皮内疫苗接种(SBRT前2周开始,共6次,每2周1次,每次1 mg)。治疗安全可行,未观察到与IMM-101相关的不良事件;1年无进展生存率为47%,中位无进展生存期为11.7个月,中位总生存期为19.0个月;加用IMM-101未显示无进展生存改善。

要点

  • 38例无进展局部晚期胰腺癌患者接受SBRT联合IMM-101治疗,安全性可行。
  • 观察到1例5级、0例4级、13例3级不良事件,均与IMM-101无关。
  • 1年PFS率47%,中位PFS 11.7个月,中位OS 19.0个月,加用IMM-101未改善PFS。

核心结论

  • IMM-101联合SBRT治疗(改良)FOLFIRINOX后无进展的局部晚期胰腺癌安全可行。
  • 在SBRT基础上加用IMM-101未显示无进展生存改善。

研究设计与样本

  • I/II期试验,纳入38例(改良)FOLFIRINOX治疗后无进展的局部晚期胰腺癌患者并开始研究治疗。
  • SBRT总剂量40 Gy,每次8 Gy,连续5天;IMM-101从SBRT前2周开始,每2周皮内接种1 mg,共6次。
  • 主要结局为4级或以上不良事件数量及1年无进展生存率。

主要发现

  • 中位随访28.4个月(95%CI 24.3-32.6)。
  • 观察到1例5级、0例4级、13例3级不良事件,均与IMM-101无关。
  • 1年无进展生存率为47%,中位无进展生存期11.7个月(95%CI 11.0-12.5),中位总生存期19.0个月(95%CI 16.2-21.9)。
  • 8例(21%)肿瘤被切除,其中6例(75%)为R0切除。
  • 结局与既往LAPC-1试验中未接受IMM-101的SBRT治疗患者相当。

关键数值与推荐

  • SBRT总剂量40 Gy,分5次,每次8 Gy。
  • IMM-101每次1 mg,皮内接种,每2周1次,共6次,从SBRT前2周开始。
  • 主要结局指标为4级或以上不良事件数量及1年无进展生存率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In this phase I/II trial, non-progressive locally advanced pancreatic cancer (LAPC) patients after (modified)FOLFIRINOX therapy were treated with stereotactic body radiotherapy (SBRT) combined with heat-killed mycobacterium (IMM-101) vaccinations. We aimed to assess safety, feasibility, and efficacy of this treatment approach. MATERIALS AND METHODS: On five consecutive days, patients received a total of 40 Gray (Gy) of SBRT with a dose of 8 Gy per fraction. Starting two weeks prior to SBRT, they in addition received six bi-weekly intradermal vaccinations with one milligram of IMM-101. The primary outcomes were the number of grade 4 or higher adverse events and the one-year progression free-survival (PFS) rate. RESULTS: Thirty-eight patients were included and started study treatment. Median follow-up was 28.4 months (95 %CI 24.3 - 32.6). We observed one grade 5, no grade 4 and thirteen grade 3 adverse events, none related to IMM-101. The one-year PFS rate was 47 %, the median PFS was 11.7 months (95 %CI 11.0 - 12.5) and the median overall survival was 19.0 months (95 %CI 16.2 - 21.9). Eight (21 %) tumors were resected, of which 6 (75 %) were R0 resections. Outcomes were comparable with the outcomes of the patients from the previous LAPC-1 trial, in which LAPC patients were treated with SBRT, without IMM-101. CONCLUSION: Combination treatment with IMM-101 and SBRT was safe and feasible for non-progressive locally advanced pancreatic cancer patients after (modified)FOLFIRINOX. No improvement in the progression-free survival could be demonstrated by adding IMM-101 to SBRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. van 't Land FR, Latifi D, Moskie M, et al. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX - The LAPC-2 trial. Radiother Oncol. 2023. PMID: 36813171. doi:10.1016/j.radonc.2023.109541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。